Lowers the risk of sustained estimated glomerular filtration rate (eGFR) decline…. Sold as Kerendia. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 14, 2026, FDA lists 2 applications for Finerenone (sold as Kerendia), first approved Jul 9, 2021, with 3 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Kerendia | Part D | $589M | +49% | 121,794 |
| Finerenone's Impact on Cardiac Electrical Stability in HFpEFHeart Failure and Preserved Ejection Fraction, Atrial Fibrillation (AF) · Assiut University | — | Not yet recruiting | Oct 8, 2026 |
| Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaObesity; Chronic Kidney Disease; Albuminuria · Peking University People's Hospital | Not applicable | Not yet recruiting | Sep 30, 2026 |
| A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b · Bayer | — | Not yet recruiting | Sep 25, 2026 |
| Finerenone and Cardiac Remodeling in HFpEFHeart Failure With Preserved Ejection Fraction · Assiut University | Phase 4 | Not yet recruiting | Sep 21, 2026 |
| Finerenone for Premature Ovarian Insufficiency (POI)Premature Ovarian Insufficiency · The University of Hong Kong-Shenzhen Hospital | Phase 2 | Not yet recruiting | Sep 11, 2026 |
| Finerenone After Catheter Ablation to Reduce Atrial Fibrillation RecurrenceAtrial Fibrillation (AF) · National Cheng-Kung University Hospital | Phase 2 | Recruiting | Sep 2, 2026 |
| QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyType 2 Diabetic Kidney Disease · Huijie Zhang | Phase 4 | Recruiting | Aug 20, 2026 |
| Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot TrialAcute Kidney Injury, Renal Insufficiency,Chronic · Jean-Maxime Côté | Not applicable | Not yet recruiting | Aug 20, 2026 |
| Jul 9, 2021 | KerendiaNDA 215341 · New molecular entity | Bayer Hlthcare | 3 | Marketed |
| — | FinerenoneANDA 220684 | Apotex Inc | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA